Navigation Links
Advanced Life Sciences to Present at 8th Annual BIO Investor Forum

CHICAGO, Oct. 13 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases, today announced that it will present at the BIO Investor Forum held October 28-29th in San Francisco.


Advanced Life Sciences' President and Chief Financial Officer, John Flavin, will make a corporate presentation to investors on Thursday, October 29th at 9:30 AM PT. The Company's presentation will be delivered in the Pacific Heights Room at The Palace Hotel, 2 New Montgomery Street in San Francisco. The webcast can be accessed through the Investor Relations page on the Advanced Life Sciences website, Those interested in listening to the presentation should log on a few minutes in advance in order to download any software or complete any sign-in that may be required.

About Restanza

Restanza is a novel, once-a-day, oral antibiotic that is in late stage development for the treatment of Community Acquired Pneumonia (CAP). It has shown higher in vitro potency and a broader range of activity than macrolides against Gram-positive bacteria associated with respiratory tract infections, and, again in in vitro tests, it appears to be effective against penicillin-, macrolide- and fluoroquinolone-resistant bacteria. Restanza's demonstrated potency and ability to overcome bacterial resistance may be due to its mechanism of action resulting in specificity for its bacterial target. In addition to its utility in CAP, Restanza is also being investigated for the prophylactic treatment of inhalation anthrax post-exposure and other high priority biodefense pathogens, including plague and tularemia. The FDA has designated Restanza as an orphan drug for the prophylactic treatment of inhalation anthrax post exposure, as well as for use in treating plague and tularemia, but the drug is not yet approved for these or any other indications.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer, respiratory diseases and biodefense. For more information, please visit us on the web at

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

SOURCE Advanced Life Sciences Holdings, Inc.

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
2. Argonne's Advanced Photon Source Lit the Way to Chemistry Nobel
3. Advanced Health Media Named to 2009 InformationWeek 500 List of Top Technology Innovators Across America
4. Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients
5. Enerkem Announces Construction Start on Advanced Energy Research Facility in Edmonton, Alberta
6. Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer
7. Hanson Technologies, Inc. Awarded Patent for its Advanced Food Pathogen Detection System
8. Advanced Instruments Introduces Next-Generation Web Site
9. New Sigma Advanced Genetic Engineering Labs Offers Research Community Unique Rodent Models Developed Using Exclusive Gene-Editing Technology
10. BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels
11. Advanced Life Sciences Announces Second Quarter 2009 Financial Results and Financial Outlook
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf Association (USGA) ... USGA Green Section Award. Presented annually since 1961, the USGA Green Section Award recognizes ... with turfgrass. , Clarke, of Iselin, N.J., is an extension specialist of ...
(Date:11/24/2015)... DIEGO , Nov. 24, 2015 Halozyme Therapeutics, Inc. ... Healthcare Conference in New York on Wednesday, ... Helen Torley , president and CEO, will provide a corporate ... New York at 1:00 p.m. ET/10:00 a.m. PT ... and investor relations, will provide a corporate overview. --> ...
(Date:11/24/2015)... Mass. (PRWEB) , ... November 24, 2015 , ... ... to maintain healthy metabolism. But unless it is bound to proteins, copper is ... of Health (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic ...
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - Aeterna ... request of IIROC on behalf of the Toronto Stock ... news release there are no corporate developments that would ... --> --> About ... . --> Aeterna Zentaris is ...
Breaking Biology Technology:
(Date:10/29/2015)... ANN ARBOR, Mich. , Oct. 29, 2015 ... with Eurofins Genomics for U.S. distribution of its ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq ... DNA to enable the preparation of NGS libraries ... in plasma for diagnostic and prognostic applications in ...
(Date:10/27/2015)... -- Munich, Germany , October ... automatically maps data from mobile eye tracking videos created ... that they can be quantitatively analyzed with SMI,s analysis ... , October 28-29, 2015. SMI,s Automated Semantic Gaze ... tracking videos created with SMI,s Eye Tracking Glasses ...
(Date:10/23/2015)... , Oct. 23, 2015 Research and Markets ... "Global Voice Recognition Biometrics Market 2015-2019" report ... --> The global voice recognition biometrics market ... --> --> ... been prepared based on an in-depth market analysis with ...
Breaking Biology News(10 mins):